Log in

NYSE:ZTSZoetis Competitors & Alternatives

$156.93
-1.16 (-0.73 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
$156.66
Now: $156.93
$159.47
50-Day Range
$131.98
MA: $143.91
$161.33
52-Week Range
$90.14
Now: $156.93
$163.98
Volume1.14 million shs
Average Volume2.27 million shs
Market Capitalization$74.56 billion
P/E Ratio46.57
Dividend Yield0.51%
Beta0.8

Competitors

Zoetis (NYSE:ZTS) Vs. JNJ, PFE, MRK, ABBV, LLY, and BMY

Should you be buying ZTS stock or one of its competitors? Companies in the sub-industry of "pharmaceuticals" are considered alternatives and competitors to Zoetis, including Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly And Co (LLY), and Bristol-Myers Squibb (BMY).

Zoetis (NYSE:ZTS) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, dividends, valuation and profitability.

Volatility & Risk

Zoetis has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500.

Institutional & Insider Ownership

91.4% of Zoetis shares are owned by institutional investors. Comparatively, 68.4% of Johnson & Johnson shares are owned by institutional investors. 0.2% of Zoetis shares are owned by insiders. Comparatively, 0.3% of Johnson & Johnson shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Dividends

Zoetis pays an annual dividend of $0.80 per share and has a dividend yield of 0.5%. Johnson & Johnson pays an annual dividend of $4.04 per share and has a dividend yield of 2.7%. Zoetis pays out 22.0% of its earnings in the form of a dividend. Johnson & Johnson pays out 46.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has raised its dividend for 1 consecutive years and Johnson & Johnson has raised its dividend for 24 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Zoetis and Johnson & Johnson, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zoetis08712.56
Johnson & Johnson041202.75

Zoetis currently has a consensus price target of $149.00, suggesting a potential downside of 5.05%. Johnson & Johnson has a consensus price target of $164.2667, suggesting a potential upside of 11.77%. Given Johnson & Johnson's stronger consensus rating and higher probable upside, analysts clearly believe Johnson & Johnson is more favorable than Zoetis.

Profitability

This table compares Zoetis and Johnson & Johnson's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zoetis25.50%63.89%14.99%
Johnson & Johnson22.69%35.21%13.60%

Valuation and Earnings

This table compares Zoetis and Johnson & Johnson's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zoetis$6.26 billion11.91$1.50 billion$3.6443.11
Johnson & Johnson$82.06 billion4.72$15.12 billion$8.6816.93

Johnson & Johnson has higher revenue and earnings than Zoetis. Johnson & Johnson is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Zoetis (NYSE:ZTS) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, dividends, valuation and profitability.

Valuation and Earnings

This table compares Zoetis and Pfizer's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zoetis$6.26 billion11.91$1.50 billion$3.6443.11
Pfizer$51.75 billion4.06$16.27 billion$2.9512.81

Pfizer has higher revenue and earnings than Zoetis. Pfizer is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Zoetis and Pfizer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zoetis25.50%63.89%14.99%
Pfizer28.80%25.11%9.52%

Dividends

Zoetis pays an annual dividend of $0.80 per share and has a dividend yield of 0.5%. Pfizer pays an annual dividend of $1.52 per share and has a dividend yield of 4.0%. Zoetis pays out 22.0% of its earnings in the form of a dividend. Pfizer pays out 51.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has raised its dividend for 1 consecutive years and Pfizer has raised its dividend for 1 consecutive years.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Zoetis and Pfizer, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zoetis08712.56
Pfizer08402.33

Zoetis currently has a consensus price target of $149.00, suggesting a potential downside of 5.05%. Pfizer has a consensus price target of $38.8583, suggesting a potential upside of 2.83%. Given Pfizer's higher probable upside, analysts clearly believe Pfizer is more favorable than Zoetis.

Volatility & Risk

Zoetis has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500.

Institutional & Insider Ownership

91.4% of Zoetis shares are owned by institutional investors. Comparatively, 70.2% of Pfizer shares are owned by institutional investors. 0.2% of Zoetis shares are owned by insiders. Comparatively, 0.1% of Pfizer shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Zoetis beats Pfizer on 12 of the 17 factors compared between the two stocks.

Merck & Co., Inc. (NYSE:MRK) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, earnings and profitability.

Valuation & Earnings

This table compares Merck & Co., Inc. and Zoetis' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merck & Co., Inc.$46.84 billion4.37$9.84 billion$5.1915.59
Zoetis$6.26 billion11.91$1.50 billion$3.6443.11

Merck & Co., Inc. has higher revenue and earnings than Zoetis. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Merck & Co., Inc. and Zoetis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Merck & Co., Inc.22.20%52.94%16.50%
Zoetis25.50%63.89%14.99%

Dividends

Merck & Co., Inc. pays an annual dividend of $2.44 per share and has a dividend yield of 3.0%. Zoetis pays an annual dividend of $0.80 per share and has a dividend yield of 0.5%. Merck & Co., Inc. pays out 47.0% of its earnings in the form of a dividend. Zoetis pays out 22.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Merck & Co., Inc. has increased its dividend for 1 consecutive years and Zoetis has increased its dividend for 1 consecutive years.

Analyst Recommendations

This is a summary of recent ratings for Merck & Co., Inc. and Zoetis, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Merck & Co., Inc.021202.86
Zoetis08712.56

Merck & Co., Inc. presently has a consensus target price of $94.9286, suggesting a potential upside of 17.33%. Zoetis has a consensus target price of $149.00, suggesting a potential downside of 5.05%. Given Merck & Co., Inc.'s stronger consensus rating and higher probable upside, research analysts plainly believe Merck & Co., Inc. is more favorable than Zoetis.

Volatility and Risk

Merck & Co., Inc. has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500.

Institutional & Insider Ownership

74.3% of Merck & Co., Inc. shares are held by institutional investors. Comparatively, 91.4% of Zoetis shares are held by institutional investors. 0.3% of Merck & Co., Inc. shares are held by insiders. Comparatively, 0.2% of Zoetis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Merck & Co., Inc. beats Zoetis on 9 of the 17 factors compared between the two stocks.

AbbVie (NYSE:ABBV) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, earnings and profitability.

Institutional & Insider Ownership

72.4% of AbbVie shares are held by institutional investors. Comparatively, 91.4% of Zoetis shares are held by institutional investors. 0.1% of AbbVie shares are held by insiders. Comparatively, 0.2% of Zoetis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares AbbVie and Zoetis' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbbVie$33.27 billion4.92$7.88 billion$8.9410.37
Zoetis$6.26 billion11.91$1.50 billion$3.6443.11

AbbVie has higher revenue and earnings than Zoetis. AbbVie is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares AbbVie and Zoetis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbbVie19.20%-628.57%14.66%
Zoetis25.50%63.89%14.99%

Volatility and Risk

AbbVie has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for AbbVie and Zoetis, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AbbVie031402.82
Zoetis08712.56

AbbVie presently has a consensus target price of $107.00, suggesting a potential upside of 15.46%. Zoetis has a consensus target price of $149.00, suggesting a potential downside of 5.05%. Given AbbVie's stronger consensus rating and higher probable upside, research analysts plainly believe AbbVie is more favorable than Zoetis.

Dividends

AbbVie pays an annual dividend of $4.72 per share and has a dividend yield of 5.1%. Zoetis pays an annual dividend of $0.80 per share and has a dividend yield of 0.5%. AbbVie pays out 52.8% of its earnings in the form of a dividend. Zoetis pays out 22.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. AbbVie has increased its dividend for 1 consecutive years and Zoetis has increased its dividend for 1 consecutive years.

Summary

Zoetis beats AbbVie on 9 of the 17 factors compared between the two stocks.

Eli Lilly And Co (NYSE:LLY) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.

Insider and Institutional Ownership

77.3% of Eli Lilly And Co shares are owned by institutional investors. Comparatively, 91.4% of Zoetis shares are owned by institutional investors. 0.1% of Eli Lilly And Co shares are owned by insiders. Comparatively, 0.2% of Zoetis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Eli Lilly And Co and Zoetis' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eli Lilly And Co$22.32 billion6.46$8.32 billion$6.0424.94
Zoetis$6.26 billion11.91$1.50 billion$3.6443.11

Eli Lilly And Co has higher revenue and earnings than Zoetis. Eli Lilly And Co is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Eli Lilly And Co and Zoetis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eli Lilly And Co24.48%183.80%15.63%
Zoetis25.50%63.89%14.99%

Risk & Volatility

Eli Lilly And Co has a beta of 0.21, suggesting that its stock price is 79% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Eli Lilly And Co and Zoetis, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eli Lilly And Co04712.75
Zoetis08712.56

Eli Lilly And Co presently has a consensus target price of $169.7273, suggesting a potential upside of 12.68%. Zoetis has a consensus target price of $149.00, suggesting a potential downside of 5.05%. Given Eli Lilly And Co's stronger consensus rating and higher probable upside, equities analysts clearly believe Eli Lilly And Co is more favorable than Zoetis.

Dividends

Eli Lilly And Co pays an annual dividend of $2.96 per share and has a dividend yield of 2.0%. Zoetis pays an annual dividend of $0.80 per share and has a dividend yield of 0.5%. Eli Lilly And Co pays out 49.0% of its earnings in the form of a dividend. Zoetis pays out 22.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Eli Lilly And Co has increased its dividend for 1 consecutive years and Zoetis has increased its dividend for 1 consecutive years.

Summary

Eli Lilly And Co beats Zoetis on 8 of the 15 factors compared between the two stocks.

Bristol-Myers Squibb (NYSE:BMY) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.

Profitability

This table compares Bristol-Myers Squibb and Zoetis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bristol-Myers Squibb-1.61%28.47%10.79%
Zoetis25.50%63.89%14.99%

Dividends

Bristol-Myers Squibb pays an annual dividend of $1.80 per share and has a dividend yield of 2.9%. Zoetis pays an annual dividend of $0.80 per share and has a dividend yield of 0.5%. Bristol-Myers Squibb pays out 38.4% of its earnings in the form of a dividend. Zoetis pays out 22.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol-Myers Squibb has increased its dividend for 1 consecutive years and Zoetis has increased its dividend for 1 consecutive years.

Analyst Ratings

This is a summary of recent recommendations and price targets for Bristol-Myers Squibb and Zoetis, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bristol-Myers Squibb031302.81
Zoetis08712.56

Bristol-Myers Squibb presently has a consensus target price of $69.2857, suggesting a potential upside of 9.75%. Zoetis has a consensus target price of $149.00, suggesting a potential downside of 5.05%. Given Bristol-Myers Squibb's stronger consensus rating and higher probable upside, equities analysts clearly believe Bristol-Myers Squibb is more favorable than Zoetis.

Insider and Institutional Ownership

74.2% of Bristol-Myers Squibb shares are owned by institutional investors. Comparatively, 91.4% of Zoetis shares are owned by institutional investors. 0.1% of Bristol-Myers Squibb shares are owned by insiders. Comparatively, 0.2% of Zoetis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

Bristol-Myers Squibb has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.

Earnings & Valuation

This table compares Bristol-Myers Squibb and Zoetis' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bristol-Myers Squibb$26.15 billion5.46$3.44 billion$4.6913.46
Zoetis$6.26 billion11.91$1.50 billion$3.6443.11

Bristol-Myers Squibb has higher revenue and earnings than Zoetis. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Summary

Zoetis beats Bristol-Myers Squibb on 10 of the 17 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Johnson & Johnson logo
JNJ
Johnson & Johnson
2.4$146.97-0.7%$386.95 billion$82.06 billion21.49Decrease in Short Interest
Pfizer logo
PFE
Pfizer
2.7$37.79-1.6%$209.99 billion$51.75 billion15.00Insider Buying
Merck & Co., Inc. logo
MRK
Merck & Co., Inc.
2.1$80.91-1.9%$204.64 billion$46.84 billion19.73
AbbVie logo
ABBV
AbbVie
2.4$92.67-0.3%$163.04 billion$33.27 billion19.72Decrease in Short Interest
Eli Lilly And Co logo
LLY
Eli Lilly And Co
2.0$150.63-1.6%$144.92 billion$22.32 billion24.45Increase in Short Interest
Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb
1.8$63.13-2.1%$139.88 billion$26.15 billion-631.24Earnings Announcement
Analyst Report
Unusual Options Activity
Royalty Pharma logo
RPRX
Royalty Pharma
1.9$45.77-0.0%$27.35 billionN/A0.00Earnings Announcement
Heavy News Reporting
Horizon Therapeutics logo
HZNP
Horizon Therapeutics
1.5$71.67-5.8%$14.80 billion$1.30 billion29.37Analyst Report
Increase in Short Interest
Analyst Revision
Mylan logo
MYL
Mylan
1.4$16.64-1.7%$8.67 billion$11.50 billion31.40Earnings Announcement
Analyst Report
Increase in Short Interest
Analyst Revision
Perrigo logo
PRGO
Perrigo
2.4$52.97-2.3%$7.30 billion$4.84 billion30.44Insider Buying
Decrease in Short Interest
Analyst Revision
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.6$122.67-3.0%$6.84 billion$2.16 billion53.10Analyst Revision
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.6$20.40-4.7%$3.71 billion$114.62 million-8.40Earnings Announcement
Heavy News Reporting
Pacira Biosciences logo
PCRX
Pacira Biosciences
1.4$59.96-1.7%$2.58 billion$421.03 million-239.84Earnings Announcement
Analyst Report
Increase in Short Interest
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.4$13.51-2.3%$1.57 billion$306.49 million14.37
Zogenix logo
ZGNX
Zogenix
1.4$24.74-0.7%$1.37 billion$3.65 million-2.60Unusual Options Activity
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.7$22.81-1.0%$1.22 billion$392.76 million10.51Upcoming Earnings
High Trading Volume
Omeros logo
OMER
Omeros
1.5$15.89-34.2%$871.62 million$111.81 million-9.18Earnings Announcement
Analyst Downgrade
High Trading Volume
Unusual Options Activity
Endo International logo
ENDP
Endo International
1.5$3.17-5.0%$760.70 million$2.91 billion-4.53Analyst Upgrade
Analyst Revision
Assembly Biosciences logo
ASMB
Assembly Biosciences
1.3$21.06-5.9%$732.99 million$15.96 million-8.36Analyst Revision
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
1.9$4.57-0.4%$463.29 million$111.39 million91.40Increase in Short Interest
Analyst Revision
Lannett logo
LCI
Lannett
1.6$6.16-2.4%$248.15 million$655.41 million-7.51
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.5$4.37-3.2%$188.49 million$16.54 million-1.25Earnings Announcement
Analyst Upgrade
Decrease in Short Interest
Cumberland Pharmaceuticals logo
CPIX
Cumberland Pharmaceuticals
2.3$3.38-0.3%$52.00 million$47.53 million-11.27
VIVUS logo
VVUS
VIVUS
1.2$0.47-11.5%$4.18 million$69.76 million-0.17Increase in Short Interest
This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.